

ONE HUNDRED NINTH LEGISLATURE - FIRST SESSION - 2025
COMMITTEE STATEMENT
LB195

Hearing Date: Thursday January 23, 2025
Committee On: Judiciary
Introducer: Meyer
One Liner: Provide immunity for administration of naloxone, nalmefene, or other federally approved opioid overdose reversal medications

Roll Call Vote - Final Committee Action:
Advanced to General File with amendment(s)

Vote Results:

Aye: 8 Senators Bosn, DeBoer, Hallstrom, Holdcroft, McKinney, Rountree, Storer, Storm
Nay:
Absent:
Present Not Voting:

Testimony:

Proponents:

Senator Glen Meyer
Thomas Janousek
Roger Donovick

Representing:

Opening Presenter
Department of Health & Human Services
Department of Health & Human Services

Opponents:

Representing:

Neutral:

Representing:

* ADA Accommodation Written Testimony

Summary of purpose and/or changes:

Section 1:

LB 195 amends 28-470 to remove the brand name Naloxone and replaces it with the broader terminology of opioid overdose reversal medication so that generic brands of Naloxone may be prescribed, dispensed, and administered with the same protections as previously granted to Naloxone.

LB 195 also provides immunity for the administration of opioid overdose reversal medications and defines opioid overdose reversal medication as any lifesaving medication approved by the United States Food and Drug Administration for reversing an opioid overdose.

Section 2:

Repealer



Explanation of amendments:

AM 135 expands the immunity provisions to include the administration of opioid overdose reversal medications obtained over the counter.

Carolyn Bosn, Chairperson

